Huber Details Natural Refrigerant Push in Lab Equipment

Peter Huber Kältemaschinenbau, the German high-precision temperature control specialist, has outlined the engineering and regulatory shift pushing laboratory and industrial systems away from synthetic refrigerants toward natural alternatives such as R-290 propane and R-744 CO₂. Published on 7 July 2026, the analysis maps how the EU F-Gas Regulation, the Kigali Amendment and US EPA refrigerant transition rules are reshaping capital planning and long-term serviceability decisions across pharma, biotech and semiconductor labs.

The EU F-Gas Regulation has transformed refrigeration, cooling and heat-pump technology from a performance-driven market into one shaped by climate policy, pushing operators toward natural refrigerants (NRs) such as CO₂ (R-744), propane (R-290) and ammonia. Ken MacKenzie, Senior Sales Advisor at Huber, argued that refrigerant choice is now part of capital planning and risk management for laboratory customers. Performance-wise, R-290 delivers a high coefficient of performance with lower compressor energy consumption, while R-744 offers exceptional heat-recovery properties but requires high-pressure operation. R-290’s flammability is manageable in benchtop units but needs leak detection in larger systems.

Long-term serviceability is now a central commercial question, given that laboratory temperature control equipment is typically a 20-year-plus capital investment. Systems built on CFCs and HCFCs face increasingly expensive repairs as refrigerant availability declines, or eventual irreparability when supply dries up. The applications most sensitive to sustainability are those requiring 24/7 operation: long-term thermal stability testing, semiconductor production lines and chilled water supply for laboratory workflows. Huber, which employs around 450 people and has used propane since 1976, serves automotive, chemical, pharmaceutical, aerospace, semiconductor and biotechnology customers with equipment operating between -125°C and +425°C.

The commercial signal is that laboratory equipment procurement decisions are becoming as much regulatory strategy as performance choice. With the F-Gas Regulation’s phase-down schedule now well into implementation and refrigerant availability tightening, expect pharma and biotech capital committees to increasingly de-prioritise HFC-based platforms in favour of natural refrigerant systems, even where upfront costs are higher. Suppliers already positioned in the transition, including Huber, Julabo, Lauda and Thermo Fisher, stand to benefit.

For the latest updates and in-depth insights into the world of Service Engineering, including breakthrough treatments, industry trends, and regulatory news, contact Adam Tiberius today!